Jean Jacques Bienaime Purchases 5,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime purchased 5,000 shares of Immunome stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.70 per share, for a total transaction of $103,500.00. Following the completion of the purchase, the director owned 43,415 shares of the company’s stock, valued at $898,690.50. This trade represents a 13.02% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, March 11th, Jean Jacques Bienaime acquired 1,000 shares of Immunome stock. The stock was acquired at an average price of $21.55 per share, for a total transaction of $21,550.00.

Immunome Stock Performance

Shares of IMNM opened at $21.53 on Thursday. The stock has a market cap of $2.44 billion, a PE ratio of -9.05 and a beta of 2.11. Immunome, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $27.65. The firm’s 50-day simple moving average is $21.92 and its two-hundred day simple moving average is $21.31.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. Equities research analysts predict that Immunome, Inc. will post -2.26 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on IMNM shares. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Truist Financial raised Immunome to a “strong-buy” rating in a research note on Monday, May 4th. Stephens cut their target price on Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.82.

Institutional Investors Weigh In On Immunome

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. boosted its position in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA boosted its position in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Immunome in the fourth quarter worth about $30,710,000. Finally, Sofinnova Investments Inc. boosted its position in Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after purchasing an additional 1,182,426 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.